MicroBrain BT
MicroBrain Biotech (MBBT) develops and markets microfluidic devices allowing the construction of neural circuits - brain-on-chip - and new approaches to screening and Pharmacological and Toxicological evaluation in order to accelerate the development of drugs.
MBBT is developing more relevant and predictive tests (Nonclinical Assessment Models), which will also significantly reduce the use of animal tests. This objective responds to a major need, both economic (Eroom law) and ethical (REACH directive), to rethink the drug development model which is no longer sustainable as it stands (costs of drug development and costs for health systems).
Original laboratories / Establishments: IBPS - CNRS / Institut Curie
Co-founders: Mr. Brugg, Mr. JM Peyrin, Mr. Mariani, and Mr. Viovy
Director: Bernadette BUNG
